Detalhe da pesquisa
1.
Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo.
Proc Natl Acad Sci U S A
; 119(32): e2201073119, 2022 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35914167
2.
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy.
Br J Cancer
; 129(6): 1022-1031, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37507543
3.
Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples.
J Transl Med
; 18(1): 99, 2020 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-32087721
4.
HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Invest New Drugs
; 37(3): 441-451, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30062574
5.
Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.
Breast Cancer Res
; 20(1): 140, 2018 11 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30458861
6.
Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
Mol Cancer
; 22(1): 175, 2023 Oct 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37915024
7.
The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.
Invest New Drugs
; 36(4): 581-589, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29396630
8.
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
BMC Cancer
; 18(1): 965, 2018 Oct 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30305055
9.
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Breast Cancer Res
; 19(1): 87, 2017 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28750640
10.
Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
Cell Immunol
; 319: 35-42, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28735814
11.
ADAM10: a new player in breast cancer progression?
Br J Cancer
; 113(6): 945-51, 2015 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26284334
12.
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
Mol Cancer
; 13: 157, 2014 Jun 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-24958351
13.
Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells.
Cancer Chemother Pharmacol
; 93(5): 427-437, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38226983
14.
BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome.
Breast Cancer Res
; 15(4): R52, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23820017
15.
EGFR and HER2 inhibition in pancreatic cancer.
Invest New Drugs
; 31(3): 558-66, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23076814
16.
Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer.
PLoS One
; 18(3): e0282512, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36920947
17.
Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
Breast Cancer Res Treat
; 136(3): 717-27, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23117852
18.
A Systems Biology Approach to Investigate Kinase Signal Transduction Networks That Are Involved in Triple Negative Breast Cancer Resistance to Cisplatin.
J Pers Med
; 12(8)2022 Aug 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36013226
19.
Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
Invest New Drugs
; 29(5): 752-9, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20229355
20.
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Clin Cancer Res
; 27(3): 807-818, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33122343